CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine Strategies
November 3rd 2021CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.
New Drug Approvals Expand cGVHD Treatment Beyond Steroids, But Real-World Data Still Needed
October 30th 2021Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.
EC-18 Improves Length and Frequency of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 29th 2021The small molecule oral immunomodulator EC-18 reduced the duration and incidence of severe oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation.
UGN-102 Induces Durable Responses in Patients with Low-Grade Intermediate-Risk NMIBC
October 24th 2021Approximately 73% of patients with NMIBC who experienced a complete response after non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 remained disease free at 9 months.
New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast Cancer
October 23rd 2021The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.
Inguinofemoral Radiotherapy May Be Potential Alternative To Lymphadenectomy In Select Vulvar Cancer
October 21st 2021Inguinofemoral radiotherapy may be a safe alternative for patients with vulvar cancer and sentinel node micrometastases who might otherwise face the morbidity of a lymphadenectomy.
Sintilimab Plus Chemotherapy Induces Superior Survival in EGFR-Mutated Nonsquamous NSCLC
October 19th 2021Sintilimab, a bevacizumab biosimilar injection, met the primary end point of the phase 3 ORIENT-31 trial by significantly increasing progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer.